They've got risks, including drug pricing, equity concerns, supply shortages, and compound pharmacies creating inferior or incorrect products. Still, Eli Lilly is on their heels, and from a reach perspective, the media loves an underdog.

If a market doesn't have competition, it isn't a market.

So I've been tracking the media converstaions around anti-obesity drugs and diabetes medications for the last year. To put it mildly, Novo Nordisk has taken the entire drug market to the woodshed and has been dealing with its competition accordingly. #PR #Data